Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Commercial Sponsor
Idera Pharmaceuticals, Inc.
Summary
In this trial, participants will be randomised into one of two arms of treatment. In Arm A, participants will receive four 3mg/kg doses of Ipilimumab intravenously over 90 minutes in Weeks 1, 4, 7 and 10. In Arm B, participants will receive the Arm A treatment plus an IMO intratumoral injection administered as 9 doses in Weeks 1, 2, 3, 5, 8, 11, 16, 20 and 24.